TREATMENT DECISION MAKING FOR EARLY PROSTATE CANCER

描述：(申请者描述)学术生涯奖将 协助申请人实现其近期和长期的职业生涯 目标。他的直接职业目标是开发一个研究项目， 检查早期前列腺癌患者的治疗决策 癌症，这评估了一种干预措施，将减少痛苦和 促进治疗决策的制定。从长远来看，学术生涯 该奖项将帮助申请者获得心理社会方面的具体培训 肿瘤学将成为癌症预防的独立研究人员。 福克斯大通癌症中心(Fccc)提供了一个两者兼具的丰富环境。 学术和临床资源。对申请者来说是一种无价的资源 教育将是与苏珊娜·M·米勒博士合作的机会 在行为医学和癌症方面有出色背景的研究人员 预防研究。高级人员将提供进一步的支持 放射肿瘤学、泌尿学和外科领域的研究人员，以及 生物统计学。Fccc为申请者提供了大量和多样化的 人口基数。 提出了两项研究。研究一是对大学生心理状况的调查 以及决定男性治疗决策的社会因素 被诊断出患有早期前列腺癌。拟议的调查，即 迄今为止规模最大的一次，涉及寻求第二次 关于手术和放射治疗的意见，以及被 在做了前列腺活检后被诊断出患有前列腺癌。病人 在决策阶段、治疗阶段和四个阶段进行面谈 在接下来的18个月中，更多地评估对 决定和性/排尿功能。研究2将纳入 来自研究1的信息，用于设计和评估干预措施 应对认知(例如，对疾病的误解)和情感 可能干扰决策的因素(例如，癌症担忧)。这个 拟议干预措施的有效性和可行性将在 随机对照试验。

DESCRIPTION: (Applicant's Description) The Academic Career Award will assist in the achievement of the applicant's immediate and long-term career goals. His immediate career goal is to develop a program of research that examines treatment decision making among men with early stage prostate cancer and that evaluates an intervention that will reduce distress and facilitates treatment decision making. In the long-term the Academic Career Award will assist the applicant to obtain specific training in psycho-social oncology to become an independent researcher in cancer prevention. Fox Chase Cancer Center (FCCC) offers an environment rich in terms of both academic and clinical resources. An invaluable resource to the applicant's education will be the opportunity to work with Dr. Suzanne M. Miller, an investigator with excellent background in behavioral medicine and cancer prevention research. Further support will be available from senior investigators in the fields of radiation oncology, urology, and surgery, and biostatistics. FCCC offers the applicant access to a large and varied population base. Two studies are proposed. Study 1 is an investigation of the psychological and social factors that determine treatment decision-making among men diagnosed with early stage prostate cancer. The proposed survey, the largest of its kind to date, involves patients who are seeking second opinions about surgery and radiation treatment, as well as patients who were diagnosed with prostate cancer after they had a prostate biopsy. Patients are interviewed during the decision making phase, treatment phase and four more times during the following 18 months, to assess satisfaction with the decision and sexual/urinary functioning. Study 2 will incorporate information from Study 1 in the design and evaluation of an intervention by addressing cognitive (e.g., misconception about the disease) and emotional factors (e.g., cancer worry) that might interfere with decision making. The efficacy and feasibility of the proposed intervention will be assessed in a randomized controlled trial.